@article{2210a2f22a724f2ba4990e7ba76ed180,
title = "A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: A high-dose study",
keywords = "Cannabinoid-1 receptor, Endocannabinoid, Randomized clinical trial",
author = "Aronne, {L. J.} and S. Tonstad and M. Moreno and I. Gantz and N. Erondu and S. Suryawanshi and C. Molony and S. Sieberts and J. Nayee and Meehan, {A. G.} and D. Shapiro and Heymsfield, {S. B.} and Kaufman, {K. D.} and Amatruda, {J. M.}",
note = "Funding Information: The study was funded by Merck & Co. The authors IG, NE, SS, CM, SS, JN, AGM, DS, SBH, KDK and JMA are or were employees of Merck & Co., Inc. and may hold stock in that company. LA and ST are members of a Merck Diabetes and Obesity Advisory Committee.",
year = "2010",
month = may,
doi = "10.1038/ijo.2010.21",
language = "English",
volume = "34",
pages = "919--935",
journal = "International Journal of Obesity",
issn = "0307-0565",
number = "5",
}